Commonly Used Quality of Life and Symptom Measurement Scales

Publication
Article
OncologyONCOLOGY Vol 16 No 9
Volume 16
Issue 9

On the following pages are examples of commonly used scales for evaluating quality of life and symptoms associated with anemia in patients with cancer. Please note that some of the scales are copyrighted (and marked as such herein) and may not be reproduced in anyway without the express written consent of the copyright holders.

On the following pages are examples of commonly used scales for evaluating quality of life and symptoms associated with anemia in patients with cancer. Please note that some of the scales are copyrighted (and marked as such herein) and may not be reproduced in anyway without the express written consent of the copyright holders.

Fatigue Symptoms Inventoty (FSI)
(Paul Jacobsen)

Multidimentional Fatigue Inventory (MFI-20)
(Ellen Smets and colleagues)

Brief Fatigue Inventory
(Charles Cleeland and colleagues)

Piper Fatigue Scale (PFS)
(Barbara Piper and colleagues)

FACIT-Fatigue Scale (Version 4)
(David Cella)

FACT-Anemia (FACT-An)
(David Cella)

EORTC: QLC-C30 (Version 3)
(Karen West)

Rotterdam Symprom Checklist
(Johanna de Haes and colleagues)

SWOG Quality of Life Questionaire
(Carol Moinpour and colleagues)

Quality of Life Index Cancer Version-III
(Carol Ferrans and Marjorie Powers)

CAncer Rehabilitation Evaluation System (CARES)
(Anne Coscarelli and Richard Heinrich)

Functional Living Index: Cancer (FLIC)
(Harvey Schipper abd Charles Olweny)

Quality of Life Index
(Cary Presant and colleagues)

L.A.S.A Scale and Quality of Lide Index Form: Form Q1
(Dianne Lindsay)

M.D. Ansderson Symptom Inventory (MDASI)
(Charles Cleeland)

McMaster Health Index Questionnaire
(Larry Chambers)

RAND 36-Item Health Survey 1.0 Questionnaire
(Judy Lewis)

 

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content